Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics

Progress in Neurobiology

Volumn 131, Issue , 2015, Pages 105-119

  Van de Velde, Sarah ^a   De Groef, Lies ^a   Stalmans, Ingeborg ^a   Moons, Lieve ^a   Van Hove, Inge ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Axonal regeneration; Glaucoma; Neuroprotection and ocular blood flow; ROCK inhibition

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADRENALIN HYDROGEN TARTRATE; COFILIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; ENDOTHELIN 1; FASUDIL; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LIM KINASE; LIM KINASE 1; LIM KINASE 2; MYOSIN LIGHT CHAIN; NEUROMODULIN; NITRIC OXIDE SYNTHASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; SEMAPHORIN 3A; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; Y 39983; RHO KINASE;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD FLOW; CELL DEATH; CELL SURVIVAL; FILTERING OPERATION; GLAUCOMA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE LESION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA GANGLION CELL; REVIEW; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; ANIMAL; ANTAGONISTS AND INHIBITORS; AXON; DRUG EFFECTS; HUMAN; METABOLISM; REGENERATION;

ANIMALS; AXONS; GLAUCOMA; HUMANS; NEUROPROTECTION; REGENERATION; RETINAL GANGLION CELLS; RHO-ASSOCIATED KINASES;

EID: 84938209755     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.06.002     Document Type: Review

References (204)

1. Addicks E.M., Quigley H.A., Green W.R., Robin A.L. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch. Ophthalmol. 1983, 101(5):795-798.
2. Agarwal R., Gupta S.K., Agarwal P., Saxena R., Agrawal S.S. Current concepts in the pathophysiology of glaucoma. Indian J. Ophthalmol. 2009, 57(4):257-266.
3. Ahmed Z., Berry M., Logan A. ROCK inhibition promotes adult retinal ganglion cell neurite outgrowth only in the presence of growth promoting factors. Mol. Cell. Neurosci. 2009, 42(2):128-133.
4. Akhter N., Nix M., Abdul Y., Singh S., Husain S. Delta-opioid receptors attenuate TNF-alpha-induced MMP-2 secretion from human ONH astrocytes. Invest. Ophthalmol. Vis. Sci. 2013, 54(10):6605-6611.
5. Alabed Y.Z., Grados-Munro E., Ferraro G.B., Hsieh S.H., Fournier A.E. Neuronal responses to myelin are mediated by rho kinase. J. Neurochem. 2006, 96(6):1616-1625.
6. Alt A., Hilgers R.D., Tura A., Nassar K., Schneider T., Hueber A., Januschowski K., Grisanti S., Luke J., Luke M. The neuroprotective potential of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in response to hypoxia in isolated bovine retina. Cell. Physiol. Biochem. 2013, 32(1):218-234.
7. Amano M., Kaneko T., Maeda A., Nakayama M., Ito M., Yamauchi T., Goto H., Fukata Y., Oshiro N., Shinohara A., Iwamatsu A., Kaibuchi K. Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J. Neurochem. 2003, 87(3):780-790.
8. Anastassiadis T., Deacon S.W., Devarajan K., Ma H., Peterson J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29(11):1039-1045.
9. Arimura N., Inagaki N., Chihara K., Menager C., Nakamura N., Amano M., Iwamatsu A., Goshima Y., Kaibuchi K. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J. Biol. Chem. 2000, 275(31):23973-23980.
10. Arita R., Hata Y., Nakao S., Kita T., Miura M., Kawahara S., Zandi S., Almulki L., Tayyari F., Shimokawa H., Hafezi-Moghadam A., Ishibashi T. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009, 58(1):215-226.
11. Baltmr A., Duggan J., Nizari S., Salt T.E., Cordeiro M.F. Neuroprotection in glaucoma-Is there a future role?. Exp. Eye Res. 2010, 91(5):554-566.
12. Bermel C., Tonges L., Planchamp V., Gillardon F., Weishaupt J.H., Dietz G.P., Bahr M., Lingor P. Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol. Cell Neurosci. 2009, 42(4):427-437.
13. Bishop A.L., Hall A. Rho GTPases and their effector proteins. Biochem. J. 2000, 348(Pt 2):241-255.
14. Bodor N., Buchwald P. Retrometabolic drug design: principles and recent developments. Pure Appl. Chem. 2008, 80(8):1669-1682.
15. Boland M.V., Quigley H.A. Risk factors and open-angle glaucoma: classification and application. J. Glaucoma 2007, 16(4):406-418.
16. Boland S., Defert O., Alen J., Bourin A., Castermans K., Kindt N., Boumans N., Panitti L., Van de Velde S., Stalmans I., Leysen D. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg. Med. Chem. Lett. 2013, 23(23):6442-6446.
17. Bonomi L., Marchini G., Marraffa M., Bernardi P., Morbio R., Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt study. Ophthalmology 2000, 107(7):1287-1293.
18. Borrajo A., Rodriguez-Perez A.I., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology 2014, 85:1-8.
19. Bos J.L., Rehmann H., Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129(5):865-877.
20. Bowerman M., Murray L.M., Boyer J.G., Anderson C.L., Kothary R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 2012, 10:24.
21. Broadway D.C., Drance S.M. Glaucoma and vasospasm. Br. J. Ophthalmol. 1998, 82(8):862-870.
22. Bull N.D., Martin K.R. Optic nerve restoration: new perspectives. J. Glaucoma 2007, 16(5):506-511.
23. Buyens T., Gaublomme D., Van Hove I., De Groef L., Moons L. Quantitative assessment of neurite outgrowth in mouse retinal explants. Methods Mol. Biol. 2014, 1162:57-71.
24. Cai D., Qiu J., Cao Z., McAtee M., Bregman B.S., Filbin M.T. Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate. J. Neurosci. 2001, 21(13):4731-4739.
25. Chang E.E., Goldberg J.L. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012, 119(5):979-986.
26. Chauhan B.C., Drance S.M. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1992, 230(6):521-526.
27. Chen J., Runyan S.A., Robinson M.R. Novel ocular antihypertensive compounds in clinical trials. Clin. Ophthalmol. 2011, 5:667-677.
28. Cheng C., Webber C.A., Wang J., Xu Y., Martinez J.A., Liu W.Q., McDonald D., Guo G.F., Nguyen M.D., Zochodne D.W. Activated RHOA and peripheral axon regeneration. Exp. Neurol. 2008, 212(2):358-369.
29. Cheung W., Guo L., Cordeiro M.F. Neuroprotection in glaucoma: drug-based approaches. Optom. Vis. Sci. 2008, 85(6):406-416.
30. Chrysostomou V., Rezania F., Trounce I.A., Crowston J.G. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol. 2013, 13(1):12-15.
31. Dahlmann-Noor A.H., Vijay S., Limb G.A., Khaw P.T. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discovery Today 2010, 15(7-8):287-299.
32. Danesh-Meyer H.V. Neuroprotection in glaucoma: recent and future directions. Curr. Opin. Ophthalmol. 2011, 22(2):78-86.
33. De Groef L., Van Hove I., Dekeyster E., Stalmans I., Moons L. MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair?. Invest. Ophthalmol. Vis. Sci. 2014, 55(3):1953-1964.
34. de Kater A.W., Spurr-Michaud S.J., Gipson I.K. Localization of smooth muscle myosin-containing cells in the aqueous outflow pathway. Invest. Ophthalmol. Vis. Sci. 1990, 31(2):347-353.
35. de Lima S., Koriyama Y., Kurimoto T., Oliveira J.T., Yin Y., Li Y., Gilbert H.Y., Fagiolini M., Martinez A.M., Benowitz L. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(23):9149-9154.
36. Deyts C., Galan-Rodriguez B., Martin E., Bouveyron N., Roze E., Charvin D., Caboche J., Betuing S. Dopamine D2 receptor stimulation potentiates polyQ-huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS ONE 2009, 4(12):e8287.
37. Ding J., Li Q.Y., Wang X., Sun C.H., Lu C.Z., Xiao B.G. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J. Neurochem. 2010, 114(6):1619-1629.
38. Ding J., Yu J.Z., Li Q.Y., Wang X., Lu C.Z., Xiao B.G. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav. Immun. 2009, 23(8):1083-1088.
39. Doe C., Bentley R., Behm D.J., Lafferty R., Stavenger R., Jung D., Bamford M., Panchal T., Grygielko E., Wright L.L., Smith G.K., Chen Z., Webb C., Khandekar S., Yi T., Kirkpatrick R., Dul E., Jolivette L., Marino J.P., Willette R., Lee D., Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 2007, 320(1):89-98.
40. Dong C.J., Guo Y., Agey P., Wheeler L., Hare W.A. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 2008, 49(10):4515-4522.
41. Duffy P., Schmandke A., Sigworth J., Narumiya S., Cafferty W.B., Strittmatter S.M. Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J. Neurosci. 2009, 29(48):15266-15276.
42. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420(6916):629-635.
43. Fechtner R.D., Weinreb R.N. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv. Ophthalmol. 1994, 39(1):23-42.
44. Fehlings M.G., Theodore N., Harrop J., Maurais G., Kuntz C., Shaffrey C.I., Kwon B.K., Chapman J., Yee A., Tighe A., McKerracher L. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 2011, 28(5):787-796.
45. Fernandes L.B., Henry P.J., Goldie R.G. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 2007, 1(1):25-33.
46. Flammer J. The vascular concept of glaucoma. Surv. Ophthalmol. 1994, 38(Suppl.):S3-S6.
47. Flammer J., Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy?. Surv. Ophthalmol. 2007, 52(Suppl. 2):S162-S173.
48. Flammer J., Orgül S., Costa V.P., Orzalesi N., Krieglstein G.K., Serra L.M., Renard J.-P., Stefánsson E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002, 21(4):359-393.
49. Flammer J., Orgul S., Costa V.P., Orzalesi N., Krieglstein G.K., Serra L.M., Renard J.P., Stefansson E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002, 21(4):359-393.
50. Fleischman D., Allingham R.R. The role of cerebrospinal fluid pressure in glaucoma and other ophthalmic diseases: a review. Saudi J. Ophthalmol. 2013, 27(2):97-106.
51. Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J. The definition and classification of glaucoma in prevalence surveys. Br. J. Ophthalmol. 2002, 86(2):238-242.
52. Fournier A.E., Takizawa B.T., Strittmatter S.M. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 2003, 23(4):1416-1423.
53. Friedman D.S., Wolfs R.C., O'Colmain B.J., Klein B.E., Taylor H.R., West S., Leske M.C., Mitchell P., Congdon N., Kempen J. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004, 122(4):532-538.
54. Froger N., Cadetti L., Lorach H., Martins J., Bemelmans A.P., Dubus E., Degardin J., Pain D., Forster V., Chicaud L., Ivkovic I., Simonutti M., Fouquet S., Jammoul F., Leveillard T., Benosman R., Sahel J.A., Picaud S. Taurine provides neuroprotection against retinal ganglion cell degeneration. PLoS ONE 2012, 7(10):e42017.
55. Fujita Y., Yamashita T. Axon growth inhibition by RhoA/ROCK in the central nervous system. Front. Neurosci. 2014, 8:338.
56. Fukunaga T., Ikesugi K., Nishio M., Sugimoto M., Sasoh M., Hidaka H., Uji Y. The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading. Curr. Eye Res. 2009, 34(1):42-47.
57. Gallo G. RhoA-kinase coordinates F-actin organization and myosin II activity during semaphorin-3A-induced axon retraction. J. Cell Sci. 2006, 119(Pt 16):3413-3423.
58. Gao C., Huang L., Long Y., Zheng J., Yang J., Pu S., Xie L. Y-39983, a selective Rho-kinase inhibitor, attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination. Neuroimmunomodulation 2013, 20(6):334-340.
59. Gaublomme D., Buyens T., Moons L. Automated analysis of neurite outgrowth in mouse retinal explants. J. Biomol. Screen. 2013, 18(5):534-543.
60. Goel M., Picciani R.G., Lee R.K., Bhattacharya S.K. Aqueous humor dynamics: a review. Open Ophthalmol. J. 2010, 4:52-59.
61. Goldhagen B., Proia A.D., Epstein D.L., Rao P.V. Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma. J. Glaucoma 2012, 21(8):530-538.
62. Gopalakrishnan S.M., Teusch N., Imhof C., Bakker M.H., Schurdak M., Burns D.J., Warrior U. Role of Rho kinase pathway in chondroitin sulfate proteoglycan-mediated inhibition of neurite outgrowth in PC12 cells. J. Neurosci. Res. 2008, 86(10):2214-2226.
63. Gungabissoon R.A., Bamburg J.R. Regulation of growth cone actin dynamics by ADF/cofilin. J. Histochem. Cytochem. 2003, 51(4):411-420.
64. Gunther R., Saal K.A., Suhr M., Scheer D., Koch J.C., Bahr M., Lingor P., Tonges L. The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice. Front. Neurosci. 2014, 8:304.
65. Hasegawa Y., Fujitani M., Hata K., Tohyama M., Yamagishi S., Yamashita T. Promotion of axon regeneration by myelin-associated glycoprotein and Nogo through divergent signals downstream of Gi/G. J. Neurosci. 2004, 24(30):6826-6832.
66. Hashimoto R., Nakamura Y., Goto H., Wada Y., Sakoda S., Kaibuchi K., Inagaki M., Takeda M. Domain- and site-specific phosphorylation of bovine NF-L by Rho-associated kinase. Biochem. Biophys. Res. Commun. 1998, 245(2):407-411.
67. Hayreh S.S. The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv. Ophthalmol. 1999, 43(Suppl. 1):S27L 42.
68. Hayreh S.S., Zimmerman M.B., Podhajsky P., Alward W.L. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am. J. Ophthalmol. 1994, 117(5):603-624.
69. He Y., Xu H., Liang L., Zhan Z., Yang X., Yu X., Ye Y., Sun L. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum. 2008, 58(11):3366-3376.
70. Hernandez M.R. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog. Retin. Eye Res. 2000, 19(3):297-321.
71. Herskowitz J.H., Feng Y., Mattheyses A.L., Hales C.M., Higginbotham L.A., Duong D.M., Montine T.J., Troncoso J.C., Thambisetty M., Seyfried N.T., Levey A.I., Lah J.J. Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer's disease mouse model. J. Neurosci. 2013, 33(49):19086-19098.
72. Hiraga A., Kuwabara S., Doya H., Kanai K., Fujitani M., Taniguchi J., Arai K., Mori M., Hattori T., Yamashita T. Rho-kinase inhibition enhances axonal regeneration after peripheral nerve injury. J. Peripher. Nerv. Syst. 2006, 11(3):217-224.
73. Hirata A., Inatani M., Inomata Y., Yonemura N., Kawaji T., Honjo M., Tanihara H. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246(1):51-59.
74. Honjo M., Inatani M., Kido N., Sawamura T., Yue B.Y., Honda Y., Tanihara H. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch. Ophthalmol. 2001, 119(8):1171-1178.
75. Honjo M., Tanihara H., Inatani M., Kido N., Sawamura T., Yue B.Y., Narumiya S., Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci. 2001, 42(1):137-144.
76. Honjo M., Tanihara H., Kameda T., Kawaji T., Yoshimura N., Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 2007, 48(12):5549-5557.
77. Ichikawa M., Yoshida J., Saito K., Sagawa H., Tokita Y., Watanabe M. Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats. Brain Res. 2008, 1201:23-33.
78. Isobe T., Mizuno K., Kaneko Y., Ohta M., Koide T., Tanabe S. Effects of k-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr. Eye Res. 2014, 39(8):813-822.
79. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5(2):221-225.
80. Ji J.Z., Elyaman W., Yip H.K., Lee V.W., Yick L.W., Hugon J., So K.F. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur. J. Neurosci. 2004, 19(2):265-272.
81. Ji J.Z., Elyaman W., Yip H.K., Lee V.W., Yick L.W., Hugon J., So K.F. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur. J. Neurosci. 2004, 19(2):265-272.
82. Johnson E.C., Morrison J.C. Friend or foe? Resolving the impact of glial responses in glaucoma. J. Glaucoma 2009, 18(5):341-353.
83. Johnson T.V., Bull N.D., Martin K.R. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp. Eye Res. 2011, 93(2):196-203.
84. Kaneko-Kawano T., Takasu F., Naoki H., Sakumura Y., Ishii S., Ueba T., Eiyama A., Okada A., Kawano Y., Suzuki K. Dynamic regulation of myosin light chain phosphorylation by Rho-kinase. PLoS ONE 2012, 7(6):e39269.
85. Kaplan D.R., Miller F.D. Axon growth inhibition: signals from the p75 neurotrophin receptor. Nat. Neurosci. 2003, 6(5):435-436.
86. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., Wilson M.R., Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120(6):701-713. discussion 829-730.
87. Kast R., Schirok H., Figueroa-Perez S., Mittendorf J., Gnoth M.J., Apeler H., Lenz J., Franz J.K., Knorr A., Hutter J., Lobell M., Zimmermann K., Munter K., Augstein K.H., Ehmke H., Stasch J.P. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br. J. Pharmacol. 2007, 152(7):1070-1080.
88. Kirwan R.P., Crean J.K., Fenerty C.H., Clark A.F., O'Brien C.J. Effect of cyclical mechanical stretch and exogenous transforming growth factor-beta1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J. Glaucoma 2004, 13(4):327-334.
89. Kitaoka Y., Kumai T., Lam T.T., Kuribayashi K., Isenoumi K., Munemasa Y., Motoki M., Kobayashi S., Ueno S. Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res. 2004, 1018(1):111-118.
90. Koch J.C., Tonges L., Barski E., Michel U., Bahr M., Lingor P. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis. 2014, 5:e1225.
91. Koumura A., Hamanaka J., Kawasaki K., Tsuruma K., Shimazawa M., Hozumi I., Inuzuka T., Hara H. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. J. Pharmacol. Exp. Ther. 2011, 338(1):337-344.
92. Krishnamoorthy R.R., Clark A.F., Daudt D., Vishwanatha J.K., Yorio T. A forensic path to RGC-5 cell line identification: lessons learned. Invest. Ophthalmol. Vis. Sci. 2013, 54(8):5712-5719.
93. Krupin T., Liebmann J.M., Greenfield D.S., Ritch R., Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am. J. Ophthalmol. 2011, 151(4):671-681.
94. Kubo T., Yamaguchi A., Iwata N., Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther. Clin. Risk Manage. 2008, 4(3):605-615.
95. Kume H. RhoA/Rho-kinase as a therapeutic target in asthma. Curr. Med. Chem. 2008, 15(27):2876-2885.
96. Labandeira-Garcia J.L., Rodriguez-Perez A.I., Villar-Cheda B., Borrajo A., Dominguez-Meijide A., Guerra M.J. Rho kinase and dopaminergic degeneration: a promising therapeutic target for Parkinson's disease. Neuroscientist 2014.
97. Lai R.K., Chun T., Hasson D., Lee S., Mehrbod F., Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis. Neurosci. 2002, 19(2):175-185.
98. Lee D.A., Higginbotham E.J. Glaucoma and its treatment: a review. Am. J. Health Syst. Pharm. 2005, 62(7):691-699.
99. Lehwalder D., Jeffrey P.L., Unsicker K. Survival of purified embryonic chick retinal ganglion cells in the presence of neurotrophic factors. J. Neurosci. Res. 1989, 24(2):329-337.
100. Leibinger M., Muller A., Andreadaki A., Hauk T.G., Kirsch M., Fischer D. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J. Neurosci. 2009, 29(45):14334-14341.
101. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell Biol. 1996, 16(10):5313-5327.
102. Li M., Huang Y., Ma A.A., Lin E., Diamond M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 2009, 36(3):413-420.
103. Li Y.H., Yu J.Z., Liu C.Y., Zhang H., Zhang H.F., Yang W.F., Li J.L., Feng Q.J., Feng L., Zhang G.X., Xiao B.G., Ma C.G. Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. Immunology 2014, 143(2):219-229.
104. Li Z., Dong X., Wang Z., Liu W., Deng N., Ding Y., Tang L., Hla T., Zeng R., Li L., Wu D. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 2005, 7(4):399-404.
105. Liao J.K., Seto M., Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 2007, 50(1):17-24.
106. Lingor P., Teusch N., Schwarz K., Mueller R., Mack H., Bahr M., Mueller B.K. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 2007, 103(1):181-189.
107. Lingor P., Tonges L., Pieper N., Bermel C., Barski E., Planchamp V., Bahr M. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008, 131(Pt 1):250-263.
108. Llobet A., Gasull X., Gual A. Understanding trabecular meshwork physiology: a key to the control of intraocular pressure?. News Physiol. Sci. 2003, 18:205-209.
109. LoGrasso P.V., Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr. Top. Med. Chem. 2009, 9(8):704-723.
110. Lorber B., Berry M., Douglas M.R., Nakazawa T., Logan A. Activated retinal glia promote neurite outgrowth of retinal ganglion cells via apolipoprotein E. J. Neurosci. Res. 2009, 87(12):2645-2652.
111. Lorber B., Guidi A., Fawcett J.W., Martin K.R. Activated retinal glia mediated axon regeneration in experimental glaucoma. Neurobiol. Dis. 2012, 45(1):243-252.
112. Lu Z., Overby D.R., Scott P.A., Freddo T.F., Gong H. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp. Eye Res. 2008, 86(2):271-281.
113. Luo X., Salgueiro Y., Beckerman S.R., Lemmon V.P., Tsoulfas P., Park K.K. Three-dimensional evaluation of retinal ganglion cell axon regeneration and pathfinding in whole mouse tissue after injury. Exp. Neurol. 2013, 247:653-662.
114. Maier K., Rau C.R., Storch M.K., Sattler M.B., Demmer I., Weissert R., Taheri N., Kuhnert A.V., Bahr M., Diem R. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol. 2004, 14(4):378-387.
115. Mandell K.J., Kudelka R.M., Wirostko B. Rho kinase inhibitors for treatment of glaucoma. Expert Rev. Ophthalmol. 2011, 6(6):611-622.
116. Martinez-Bello C., Chauhan B.C., Nicolela M.T., McCormick T.A., LeBlanc R.P. Intraocular pressure and progression of glaucomatous visual field loss. Am. J. Ophthalmol. 2000, 129(3):302-308.
117. Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996, 15(9):2208-2216.
118. Matsuoka Y., Li X., Bennett V. Adducin: structure, function and regulation. Cell. Mol. Life Sci. 2000, 57(6):884-895.
119. McKeon R.J., Schreiber R.C., Rudge J.S., Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci. 1991, 11(11):3398-3411.
120. McKerracher L., Winton M.J. Nogo on the go. Neuron 2002, 36(3):345-348.
121. Mey J., Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. 1993, 602(2):304-317.
122. Meyer-ter-Vehn T., Sieprath S., Katzenberger B., Gebhardt S., Grehn F., Schlunck G. Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci. 2006, 47(11):4895-4904.
123. Mimura F., Yamagishi S., Arimura N., Fujitani M., Kubo T., Kaibuchi K., Yamashita T. Myelin-associated glycoprotein inhibits microtubule assembly by a Rho-kinase-dependent mechanism. J. Biol. Chem. 2006, 281(23):15970-15979.
124. Mitchell P., Hourihan F., Sandbach J., Wang J.J. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology 1999, 106(10):2010-2015.
125. Mitchell P., Smith W., Chey T., Healey P.R. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997, 104(4):712-718.
126. Monnier P.P., Sierra A., Schwab J.M., Henke-Fahle S., Mueller B.K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 2003, 22(3):319-330.
127. Morgan J.E. Circulation and axonal transport in the optic nerve. Eye (London) 2004, 18(11):1089-1095.
128. Mueller B.K., Mack H., Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discovery 2005, 4(5):387-398.
129. Muller A., Hauk T.G., Fischer D. Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation. Brain 2007, 130(Pt 12):3308-3320.
130. Murray A.J. Axon regeneration: what needs to be overcome?. Methods Mol. Biol. 2014, 1162:3-14.
131. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392(2):189-193.
132. Nakajima E., Nakajima T., Minagawa Y., Shearer T.R., Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J. Pharm. Sci. 2005, 94(4):701-708.
133. Nakazawa T., Watabe A.M., Tezuka T., Yoshida Y., Yokoyama K., Umemori H., Inoue A., Okabe S., Manabe T., Yamamoto T. p250GAP, a novel brain-enriched GTPase-activating protein for Rho family GTPases, is involved in the N-methyl-d-aspartate receptor signaling. Mol. Biol. Cell 2003, 14(7):2921-2934.
134. Ng D.C., Lin B.H., Lim C.P., Huang G., Zhang T., Poli V., Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol. 2006, 172(2):245-257.
135. Nickells R.W. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can. J. Ophthalmol. 2007, 42(2):278-287.
136. Nishio M., Fukunaga T., Sugimoto M., Ikesugi K., Sumi K., Hidaka H., Uji Y. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr. Eye Res. 2009, 34(4):282-286.
137. Norenberg W., Hofmann F., Illes P., Aktories K., Meyer D.K. Rundown of somatodendritic N-methyl-d-aspartate (NMDA) receptor channels in rat hippocampal neurones: evidence for a role of the small GTPase RhoA. Br. J. Pharmacol. 1999, 127(5):1060-1063.
138. Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 2000, 275(5):3577-3582.
139. Osborne N.N. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009, 87(4):450-454.
140. Osborne N.N., Melena J., Chidlow G., Wood J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 2001, 85(10):1252-1259.
141. Park K., Luo J.M., Hisheh S., Harvey A.R., Cui Q. Cellular mechanisms associated with spontaneous and ciliary neurotrophic factor-cAMP-induced survival and axonal regeneration of adult retinal ganglion cells. J. Neurosci. 2004, 24(48):10806-10815.
142. Pasterkamp R.J., Verhaagen J. Semaphorins in axon regeneration: developmental guidance molecules gone wrong?. Philos. Trans. R. Soc. London B Biol. Sci. 2006, 361(1473):1499-1511.
143. Pernet V., Joly S., Jordi N., Dalkara D., Guzik-Kornacka A., Flannery J.G., Schwab M.E. Misguidance and modulation of axonal regeneration by Stat3 and Rho/ROCK signaling in the transparent optic nerve. Cell Death Dis. 2013, 4:e734.
144. Pernet V., Schwab M.E. Lost in the jungle: new hurdles for optic nerve axon regeneration. Trends Neurosci. 2014, 37(7):381-387.
145. Quigley H.A. Glaucoma. Lancet 2011, 377(9774):1367-1377.
146. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90(3):262-267.
147. Quigley H.A., McKinnon S.J., Zack D.J., Pease M.E., Kerrigan-Baumrind L.A., Kerrigan D.F., Mitchell R.S. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest. Ophthalmol. Vis. Sci. 2000, 41(11):3460-3466.
148. Quill B., Docherty N.G., Clark A.F., O'Brien C.J. The effect of graded cyclic stretching on extracellular matrix-related gene expression profiles in cultured primary human lamina cribrosa cells. Invest. Ophthalmol. Vis. Sci. 2011, 52(3):1908-1915.
149. Racette L., Wilson M.R., Zangwill L.M., Weinreb R.N., Sample P.A. Primary open-angle glaucoma in blacks: a review. Surv. Ophthalmol. 2003, 48(3):295-313.
150. Rao P.V., Deng P.F., Kumar J., Epstein D.L. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest. Ophthalmol. Vis. Sci. 2001, 42(5):1029-1037.
151. Resnikoff S., Pascolini D., Mariotti S.P., Pokharel G.P. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull. World Health Organ. 2008, 86(1):63-70.
152. Riento K., Guasch R.M., Garg R., Jin B., Ridley A.J. RhoE binds to ROCK I and inhibits downstream signaling. Mol. Cell Biol. 2003, 23(12):4219-4229.
153. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003, 4(6):446-456.
154. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36(10):2251-2257.
155. Rudnicka A.R., Mt-Isa S., Owen C.G., Cook D.G., Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest. Ophthalmol. Vis. Sci. 2006, 47(10):4254-4261.
156. Sagawa H., Terasaki H., Nakamura M., Ichikawa M., Yata T., Tokita Y., Watanabe M. A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp. Neurol. 2007, 205(1):230-240.
157. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., Asano T. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001, 69(12):1441-1453.
158. Schmandke A., Strittmatter S.M. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 2007, 13(5):454-469.
159. Selvaraj B.T., Frank N., Bender F.L., Asan E., Sendtner M. Local axonal function of STAT3 rescues axon degeneration in the pmn model of motoneuron disease. J. Cell Biol. 2012, 199(3):437-451.
160. Shaw R.J., Henry M., Solomon F., Jacks T. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol. Biol. Cell 1998, 9(2):403-419.
161. Shi J., Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J. Cardiovasc. Pharmacol. 2013, 62(4):341-354.
162. Shi J., Wu X., Surma M., Vemula S., Zhang L., Yang Y., Kapur R., Wei L. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 2013, 4:e483.
163. Sigal I.A., Ethier C.R. Biomechanics of the optic nerve head. Exp. Eye Res. 2009, 88(4):799-807.
164. Silver J., Miller J.H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 2004, 5(2):146-156.
165. Sippl C., Tamm E.R. What is the nature of the RGC-5 cell line?. Adv. Exp. Med. Biol. 2014, 801:145-154.
166. Song Y., Chen X., Wang L.Y., Gao W., Zhu M.J. Rho kinase inhibitor fasudil protects against beta-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci. Ther. 2013, 19(8):603-610.
167. Stroman G.A., Stewart W.C., Golnik K.C., Cure J.K., Olinger R.E. Magnetic resonance imaging in patients with low-tension glaucoma. Arch. Ophthalmol. 1995, 113(2):168-172.
168. Sugiyama T., Shibata M., Kajiura S., Okuno T., Tonari M., Oku H., Ikeda T. Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest. Ophthalmol. Vis. Sci. 2011, 52(1):64-69.
169. Sumi T., Matsumoto K., Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 2001, 276(1):670-676.
170. Sung J.K., Miao L., Calvert J.W., Huang L., Louis Harkey H., Zhang J.H. A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res. 2003, 959(1):29-38.
171. Suzuki Y., Shibuya M., Satoh S.-i.Sugimoto Y., Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 2007, 68(2):126-131.
172. Tanihara H., Inatani M., Honjo M., Tokushige H., Azuma J., Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol. 2008, 126(3):309-315.
173. Thanos S., Naskar R., Heiduschka P. Regenerating ganglion cell axons in the adult rat establish retinofugal topography and restore visual function. Exp. Brain Res. 1997, 114(3):483-491.
174. Toft-Kehler A.K., Skytt D.M., Poulsen K.A., Braendstrup C.T., Gegelashvili G., Waagepetersen H., Kolko M. Limited energy supply in Muller cells alters glutamate uptake. Neurochem. Res 2014, 39(5):941-949.
175. Tokushige H., Inatani M., Nemoto S., Sakaki H., Katayama K., Uehata M., Tanihara H. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest. Ophthalmol. Vis. Sci. 2007, 48(7):3216-3222.
176. Tokushige H., Waki M., Takayama Y., Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr. Eye Res. 2011, 36(10):964-970.
177. Tonges L., Frank T., Tatenhorst L., Saal K.A., Koch J.C., Szego E.M., Bahr M., Weishaupt J.H., Lingor P. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 2012, 135(Pt 11):3355-3370.
178. Tonges L., Gunther R., Suhr M., Jansen J., Balck A., Saal K.A., Barski E., Nientied T., Gotz A.A., Koch J.C., Mueller B.K., Weishaupt J.H., Sereda M.W., Hanisch U.K., Bahr M., Lingor P. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 2014, 62(2):217-232.
179. Tonges L., Koch J.C., Bahr M., Lingor P. ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration. Front. Mol. Neurosci. 2011, 4:39.
180. Toshima Y., Satoh S., Ikegaki I., Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31(9):2245-2250.
181. Tsukita S., Yonemura S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends. Biochem. Sci. 1997, 22(2):53-58.
182. Tura A., Schuettauf F., Monnier P.P., Bartz-Schmidt K.U., Henke-Fahle S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest. Ophthalmol. Vis. Sci. 2009, 50(1):452-461.
183. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389(6654):990-994.
184. Van de Velde S., Van Bergen T., Sijnave D., Hollanders K., Castermans K., Defert O., Leysen D., Vandewalle E., Moons L., Stalmans I. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest. Ophthalmol. Vis. Sci. 2014, 55(2):1006-1016.
185. Van Veldhuisen P.C., Ederer F., Gaasterland D.E., Sullivan K., Beck A., Prum B.E., Cyrlin M.N., Weiss H. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 2000, 130(4):429-440.
186. Villar-Cheda B., Dominguez-Meijide A., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol. Dis. 2012, 47(2):268-279.
187. Waki M., Yoshida Y., Oka T., Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr. Eye Res. 2001, 22(6):470-474.
188. Walker K.L., Yoo H.K., Undamatla J., Szaro B.G. Loss of neurofilaments alters axonal growth dynamics. J. Neurosci. 2001, 21(24):9655-9666.
189. Wang J.J., Mitchell P., Smith W. Is there an association between migraine headache and open-angle glaucoma? Findings from the Blue Mountains Eye Study. Ophthalmology 1997, 104(10):1714-1719.
190. Weibel D., Kreutzberg G.W., Schwab M.E. Brain-derived neurotrophic factor (BDNF) prevents lesion-induced axonal die-back in young rat optic nerve. Brain Res. 1995, 679(2):249-254.
191. Weinreb R.N. Glaucoma neuroprotection: what is it? Why is it needed?. Can. J. Ophthalmol. 2007, 42(3):396-398.
192. Weinreb R.N., Khaw P.T. Primary open-angle glaucoma. Lancet 2004, 363(9422):1711-1720.
193. Weise J., Isenmann S., Klocker N., Kugler S., Hirsch S., Gravel C., Bahr M. Adenovirus-mediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized rat retinal ganglion cells but does not support axonal regeneration in vivo. Neurobiol. Dis. 2000, 7(3):212-223.
194. Wiederholt M., Thieme H., Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retin. Eye Res. 2000, 19(3):271-295.
195. Wierzbowska J., Robaszkiewicz J., Figurska M., Stankiewicz A. Future possibilities in glaucoma therapy. Med. Sci. Monit. 2010, 16(11):RA252-RA259.
196. Wolfs R.C., Klaver C.C., Ramrattan R.S., van Duijn C.M., Hofman A., de Jong P.T. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch. Ophthalmol. 1998, 116(12):1640-1645.
197. Yamamoto K., Maruyama K., Himori N., Omodaka K., Yokoyama Y., Shiga Y., Morin R., Nakazawa T. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest. Ophthalmol. Vis. Sci. 2014, 55(11):7126-7136.
198. Yamashita T., Tohyama M. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 2003, 6(5):461-467.
199. Yan D.B., Coloma F.M., Metheetrairut A., Trope G.E., Heathcote J.G., Ethier C.R. Deformation of the lamina cribrosa by elevated intraocular pressure. Br. J. Ophthalmol. 1994, 78(8):643-648.
200. Yanagi M., Kawasaki R., Wang J.J., Wong T.Y., Crowston J., Kiuchi Y. Vascular risk factors in glaucoma: a review. Clin. Exp. Ophthalmol. 2011, 39(3):252-258.
201. Zhang C.W., Lu Q., You S.W., Zhi Y., Yip H.K., Wu W., So K.F., Cui Q. CNTF and BDNF have similar effects on retinal ganglion cell survival but differential effects on nitric oxide synthase expression soon after optic nerve injury. Invest. Ophthalmol. Vis. Sci. 2005, 46(4):1497-1503.
202. Zhang Z., Ottens A.K., Larner S.F., Kobeissy F.H., Williams M.L., Hayes R.L., Wang K.K. Direct Rho-associated kinase inhibition [correction of inhibiton] induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell. Mol. Biol. Lett. 2006, 11(1):12-29.
203. Zhao J., Zhou D., Guo J., Ren Z., Zhou L., Wang S., Xu B., Wang R. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol. Med. Chir. 2006, 46(9):421-428.
204. Zhou Y., Huang X., Hecker L., Kurundkar D., Kurundkar A., Liu H., Jin T.H., Desai L., Bernard K., Thannickal V.J. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Invest. 2013, 123(3):1096-1108.